These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 2610051

  • 1. The renal kallikrein-kinin system in renoparenchymal hypertension.
    Ando T, Shimamoto K, Ura N, Yokoyama T, Fukuyama S, Yamaguchi Y, Nakagawa H, Mori Y, Ogata H, Iimura O.
    Adv Exp Med Biol; 1989; 247B():127-32. PubMed ID: 2610051
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Study on the renal kallikrein-kinin system in normal and low renin subgroups of essential hypertension.
    Iimura O, Shimamoto K, Ura N, Mita T, Tanaka S, Nishimiya T, Nakagawa M, Yamaguchi Y.
    J Hypertens Suppl; 1984 Dec; 2(3):S297-9. PubMed ID: 6100742
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Renal kallikrein-kinin, prostaglandin E2, and dopamine systems in young normotensive subjects with a family history of essential hypertension.
    Shimamoto K, Ura N, Nishimura M, Iimura O.
    Am J Med Sci; 1994 Feb; 307 Suppl 1():S70-4. PubMed ID: 8141169
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Disappearance of bradykinin in the renal circulation of dogs. Effects of kininase inhibition.
    Nasjletti A, Colina-Chourio J, McGiff JC.
    Circ Res; 1975 Jul; 37(1):59-65. PubMed ID: 167999
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Studies on kallikrein activity in diabetic patient with hypertension caused by nephropathy].
    Kunii N.
    Nihon Jinzo Gakkai Shi; 1989 Jan; 31(1):39-48. PubMed ID: 2746999
    [Abstract] [Full Text] [Related]

  • 19. The pathophysiological role of renal dopamine, kallikrein kinin and prostaglandin systems in essential hypertension.
    Iimura O, Shimamoto K, Ura N, Nakagawa M, Nishimiya T, Ando T, Yamaguchi Y, Masuda A, Ogata H, Saito S.
    Agents Actions Suppl; 1987 Jan; 22():247-56. PubMed ID: 3324711
    [Abstract] [Full Text] [Related]

  • 20. Effect of inhibiting renal kallikrein on prostaglandin E2, water, and sodium excretion.
    Saitoh S, Scicli AG, Peterson E, Carretero OA.
    Hypertension; 1995 May; 25(5):1008-13. PubMed ID: 7737707
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.